Junjie Ma
Zhejiang Provincial Key Laboratory Of Drug Discovery And Development For Metabolic Diseases
Hangzhou, 310018, China
Hangzhou, 310018, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Repurposing the Neurokinin-1 receptor antagonist Aprepitant to eradicate relapsed/refractory acute lymphoblastic leukemia via mitochondria-driven necroptosis.
Journal: Cancer letters
Published: January 06, 2026
Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells.
Journal: Cancer chemotherapy and pharmacology
Published: May 23, 2025
The cytoskeletal protein smoothelin maintains homologous recombination repair by stabilizing RAD51 in an HUWE1-dependent manner in colorectal cancer.
Journal: Acta pharmaceutica Sinica. B
Published: February 12, 2025
Milciclib-mediated CDK2 inhibition to boost radiotherapy sensitivity in colorectal cancer.
Journal: Frontiers in pharmacology
Published: January 09, 2025
Identification of ANXA1 as a Novel Upstream Negative Regulator of Notch1 Function in AML.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: August 15, 2024
Transpiration-Inspired Fabric Dressing for Acceleration Healing of Wound Infected with Biofilm.
Journal: Advanced healthcare materials
Published: March 18, 2024
Advances in the research and application of neurokinin-1 receptor antagonists.
Journal: Journal of Zhejiang University. Science. B
Published: February 02, 2024
A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 09, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026